Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 172 articles:
HTML format



Single Articles


    May 2020
  1. WEBER M, Kurek CE, Barbato F, Eiber M, et al
    PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study.
    J Nucl Med. 2020 May 22. pii: jnumed.120.245456. doi: 10.2967/jnumed.120.245456.
    PubMed     Abstract available


  2. KLINGENBERG S, Jochumsen MR, Ulhoi BP, Fredsoe J, et al
    (68)Ga-PSMA PET/CT for primary NM staging of high-risk prostate cancer.
    J Nucl Med. 2020 May 22. pii: jnumed.120.245605. doi: 10.2967/jnumed.120.245605.
    PubMed     Abstract available


  3. DITTMANN H, Kaltenbach S, Weissinger M, Fiz F, et al
    The prognostic value of quantitative bone scan SPECT/CT prior to (223)Ra treatment in metastatic castration-resistant prostate cancer (mCRPC).
    J Nucl Med. 2020 May 22. pii: jnumed.119.240408. doi: 10.2967/jnumed.119.240408.
    PubMed     Abstract available


  4. HARSINI S, Saprunoff H, Alden TM, Mohammadi B, et al
    The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
    J Nucl Med. 2020 May 8. pii: jnumed.120.246983. doi: 10.2967/jnumed.120.246983.
    PubMed     Abstract available


  5. FENDLER WP, Ferdinandus J, Czernin J, Eiber M, et al
    Impact of (68)Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.
    J Nucl Med. 2020 May 1. pii: jnumed.120.242180. doi: 10.2967/jnumed.120.242180.
    PubMed     Abstract available


  6. ZANG J, Liu Q, Sui H, Wang R, et al
    (177)Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2020 May 1. pii: jnumed.120.242263. doi: 10.2967/jnumed.120.242263.
    PubMed     Abstract available


    April 2020
  7. SEIFERT R, Herrmann K, Kleesiek J, Schafers MA, et al
    Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer.
    J Nucl Med. 2020 Apr 24. pii: jnumed.120.242057. doi: 10.2967/jnumed.120.242057.
    PubMed     Abstract available


  8. CHIU LW, Lawhn-Heath C, Behr S, Juarez R, et al
    Factors predicting metastatic disease in (68)Ga-PSMA-11 PET positive osseous lesions in prostate cancer.
    J Nucl Med. 2020 Apr 17. pii: jnumed.119.241174. doi: 10.2967/jnumed.119.241174.
    PubMed     Abstract available


  9. JADVAR H, Ballas LK, Choyke PL, Fanti S, et al
    Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment.
    J Nucl Med. 2020;61:552-562.
    PubMed    


    March 2020
  10. ORTEGA C, Schaefferkoetter J, Veit-Haibach P, Anconina R, et al
    (18)F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smooth Filter and Partial Volume Correction on Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria.
    J Nucl Med. 2020 Mar 20. pii: jnumed.120.241737. doi: 10.2967/jnumed.120.241737.
    PubMed     Abstract available


  11. DE JONG AC, Smits M, van Riet J, Futterer JJ, et al
    (68)Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic prostate cancer patients.
    J Nucl Med. 2020 Mar 13. pii: jnumed.119.241109. doi: 10.2967/jnumed.119.241109.
    PubMed     Abstract available


  12. DERLIN T, Werner RA, Lafos M, Henkenberens C, et al
    Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: a Single-Center Retrospective Study.
    J Nucl Med. 2020 Mar 13. pii: jnumed.120.241588. doi: 10.2967/jnumed.120.241588.
    PubMed     Abstract available


    February 2020
  13. GAFITA A, Heck M, Rauscher I, Tauber R, et al
    Early prostate-specific antigen changes and clinical outcome following (177)Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2020 Feb 28. pii: jnumed.119.240242. doi: 10.2967/jnumed.119.240242.
    PubMed     Abstract available


  14. BEHESHTI M, Manafi-Farid R, Geinitz H, Vali R, et al
    Multi-phasic (68)Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA < 1 ng/ml: a prospective study of 135 cases.
    J Nucl Med. 2020 Feb 14. pii: jnumed.119.238071. doi: 10.2967/jnumed.119.238071.
    PubMed     Abstract available


  15. LIU C, Liu T, Zhang Z, Zhang N, et al
    PSMA PET/CT and standard plus PET/CT-Ultrasound fusion targeted prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsies.
    J Nucl Med. 2020 Feb 7. pii: jnumed.119.235333. doi: 10.2967/jnumed.119.235333.
    PubMed     Abstract available


    January 2020
  16. JANSEN BHE, Cysouw MCF, Vis AN, van Moorselaar RJA, et al
    Repeatability of Quantitative (18)F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
    J Nucl Med. 2020 Jan 10. pii: jnumed.119.236075. doi: 10.2967/jnumed.119.236075.
    PubMed     Abstract available


  17. SONNI I, Eiber M, Fendler WP, Alano RM, et al
    Impact of (68)Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single Center Study.
    J Nucl Med. 2020 Jan 10. pii: jnumed.119.237602. doi: 10.2967/jnumed.119.237602.
    PubMed     Abstract available


    December 2019
  18. MICHAUD L, Touijer K, Mauguen A, Zelefsky M, et al
    (11)C-choline PET/CT in recurrent prostate cancer: retrospective analysis in a large US patient series.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.233098. doi: 10.2967/jnumed.119.233098.
    PubMed     Abstract available


  19. OH SW, Wurzer A, Teoh EJ, Oh S, et al
    Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of Novel Radiohybrid PSMA, (18)F- rhPSMA-7, in Patients with Prostate Cancer.
    J Nucl Med. 2019 Dec 13. pii: jnumed.119.234609. doi: 10.2967/jnumed.119.234609.
    PubMed     Abstract available


  20. EIBER M, Kronke M, Wurzer A, Ulbrich L, et al
    (18)F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy.
    J Nucl Med. 2019 Dec 13. pii: jnumed.119.234914. doi: 10.2967/jnumed.119.234914.
    PubMed     Abstract available


  21. KRONKE M, Wurzer A, Schwamborn K, Ulbrich L, et al
    Histologically-confirmed diagnostic efficacy of (18)F-rhPSMA-7 positron emission tomography for N-staging of patients with primary high risk prostate cancer.
    J Nucl Med. 2019 Dec 13. pii: jnumed.119.234906. doi: 10.2967/jnumed.119.234906.
    PubMed     Abstract available


  22. FAROLFI A, Ilhan H, Gafita A, Calais J, et al
    Mapping prostate cancer lesions pre/post unsuccessful salvage lymph node dissection using repeat PSMA-PET.
    J Nucl Med. 2019 Dec 5. pii: jnumed.119.235374. doi: 10.2967/jnumed.119.235374.
    PubMed     Abstract available


  23. BAKHT MK, Lovnicki JM, Tubman J, Stringer KF, et al
    Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for FDG imaging of PSMA-suppressed tumors.
    J Nucl Med. 2019 Dec 5. pii: jnumed.119.231068. doi: 10.2967/jnumed.119.231068.
    PubMed     Abstract available


    November 2019
  24. WANG B, Gao J, Zhang Q, Fu Y, et al
    Diagnostic value of (68)Ga-PSMA PET/CT for detection of PTEN expression in prostate cancer: a pilot study.
    J Nucl Med. 2019 Nov 22. pii: jnumed.119.236059. doi: 10.2967/jnumed.119.236059.
    PubMed     Abstract available


  25. VIOLET J, Sandhu S, Iravani A, Ferdinandus J, et al
    Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ((177)Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
    J Nucl Med. 2019 Nov 15. pii: jnumed.119.236414. doi: 10.2967/jnumed.119.236414.
    PubMed     Abstract available


  26. MEERSHOEK P, Buckle T, van Oosterom MN, KleinJan GH, et al
    Can fluorescence-guided surgery help identify all lesions in unknown locations or is the integrated use of a roadmap created by preoperative imaging mandatory? A blinded study in prostate cancer patients.
    J Nucl Med. 2019 Nov 11. pii: jnumed.119.235234. doi: 10.2967/jnumed.119.235234.
    PubMed     Abstract available


  27. MENA E, Lindenberg ML, Turkbey IB, Shih JH, et al
    (18)F-DCFPyL PET/CT Imaging in Patients with Biochemical Recurrence Prostate Cancer after Primary Local Therapy.
    J Nucl Med. 2019 Nov 1. pii: jnumed.119.234799. doi: 10.2967/jnumed.119.234799.
    PubMed     Abstract available


    October 2019
  28. DIETLEIN F, Kobe C, Hohberg M, Zlatopolskiy BD, et al
    Intraindividual comparison of (18)F-PSMA-1007 with renally excreted PSMA ligands for PSMA-PET imaging in patients with relapsed prostate cancer.
    J Nucl Med. 2019 Oct 18. pii: jnumed.119.234898. doi: 10.2967/jnumed.119.234898.
    PubMed     Abstract available


  29. SONG H, Harrison C, Duan H, Guja K, et al
    Prospective Evaluation in an Academic Center of (18)F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.
    J Nucl Med. 2019 Oct 18. pii: jnumed.119.231654. doi: 10.2967/jnumed.119.231654.
    PubMed     Abstract available


  30. ANAND A, Tragardh E, Edenbrandt L, Beckman L, et al
    Assessing Radiographic Response to Ra-223 with Automated Bone Scan Index (aBSI) in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients.
    J Nucl Med. 2019 Oct 4. pii: jnumed.119.231100. doi: 10.2967/jnumed.119.231100.
    PubMed     Abstract available


    September 2019
  31. KUTEN J, Fahoum I, Savin Z, Shamni O, et al
    Head- to head Comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard.
    J Nucl Med. 2019 Sep 27. pii: jnumed.119.234187. doi: 10.2967/jnumed.119.234187.
    PubMed     Abstract available


  32. HINSENVELD FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, et al
    Prostate-specific membrane antigen positron emission tomography/computed tomography combined with sentinel node biopsy for primary lymph node staging in prostate cancer.
    J Nucl Med. 2019 Sep 27. pii: jnumed.119.232199. doi: 10.2967/jnumed.119.232199.
    PubMed     Abstract available


  33. POMYKALA KL, Czernin J, Grogan TR, Armstrong WR, et al
    Total-body (68)Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: Potential impact on bone scan guidelines.
    J Nucl Med. 2019 Sep 20. pii: jnumed.119.230318. doi: 10.2967/jnumed.119.230318.
    PubMed     Abstract available


  34. JANSEN BHE, Jansen RW, Wondergem M, Srbljin S, et al
    Lesion Detection and Interobserver Agreement with Advanced Image-Reconstructions for (18)F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.118.222513. doi: 10.2967/jnumed.118.222513.
    PubMed     Abstract available


  35. ZACHO HD, Fonager RF, Nielsen JB, Haarmark C, et al
    Observer agreement and accuracy of (18)F-sodium-fluoride PET/CT in the diagnosis of bone metastases in prostate cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.232686. doi: 10.2967/jnumed.119.232686.
    PubMed     Abstract available


  36. ZACHO HD, Petersen LJ
    Reply LTE, Off-Target Report on (18)F-Sodium Fluoride PET/CT for Detection of Skeletal Metastases in Prostate Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.234146. doi: 10.2967/jnumed.119.234146.
    PubMed    


  37. GHAFOOR S, Burger IA, Vargas HA
    Multimodality Imaging of Prostate Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.228320. doi: 10.2967/jnumed.119.228320.
    PubMed     Abstract available


    August 2019
  38. ROWE SP, Li X, Trock BJ, Werner RA, et al
    Prospective Comparison of PET Imaging with PSMA-targeted (18)F-DCFPyL versus Na(18)F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.
    J Nucl Med. 2019 Aug 26. pii: jnumed.119.227793. doi: 10.2967/jnumed.119.227793.
    PubMed     Abstract available


  39. RAHBAR K, Morris MJ
    Is the "VISION" of Radioligand Therapy for Prostate Cancer becoming reality? An Overview of the Phase III trial and the Importance for the Future of Theranostics.
    J Nucl Med. 2019 Aug 26. pii: jnumed.119.234054. doi: 10.2967/jnumed.119.234054.
    PubMed    


  40. DAVENPORT MS, Montgomery JS, Kunju LP, Siddiqui J, et al
    (18)F-choline PET/mpMRI for Detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies.
    J Nucl Med. 2019 Aug 16. pii: jnumed.119.225789. doi: 10.2967/jnumed.119.225789.
    PubMed     Abstract available


  41. KRANZBUHLER B, Muller J, Becker AS, Garcia Schuler HI, et al
    Detection rate and localization of prostate cancer recurrence using (68)Ga-PSMA-11 PET/MRI in patients with low PSA values </= 0.5 ng/ml.
    J Nucl Med. 2019 Aug 2. pii: jnumed.118.225276. doi: 10.2967/jnumed.118.225276.
    PubMed     Abstract available


    July 2019
  42. BARNETT C, Davenport MS, Montgomery JS, Kunju LP, et al
    (18)F-choline PET/mpMRI for Detection of Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis.
    J Nucl Med. 2019 Jul 26. pii: jnumed.119.225771. doi: 10.2967/jnumed.119.225771.
    PubMed     Abstract available


  43. DIETLEIN F, Hohberg M, Kobe C, Zlatopolskiy BD, et al
    A novel (18)F-labeled PSMA ligand for PET/CT imaging of prostate cancer patients: First-in-man observational study and clinical experience with (18)F-JK-PSMA-7 during the first year of application.
    J Nucl Med. 2019 Jul 19. pii: jnumed.119.229542. doi: 10.2967/jnumed.119.229542.
    PubMed     Abstract available


  44. KOERBER SA, Stach G, Kratochwil C, Haefner MF, et al
    Lymph node involvement in treatment-naive prostate cancer patients - correlation of PSMA-PET/CT imaging and Roach formula in 280 men in the Radiotherapeutic management.
    J Nucl Med. 2019 Jul 13. pii: jnumed.119.227637. doi: 10.2967/jnumed.119.227637.
    PubMed     Abstract available


  45. HOILUND-CARLSEN PF, Alavi A
    Off-Target Report on (18)F-Sodium Fluoride PET/CT for Detection of Skeletal Metastases in Prostate Cancer.
    J Nucl Med. 2019 Jul 13. pii: jnumed.119.232348. doi: 10.2967/jnumed.119.232348.
    PubMed    


  46. LUTJE S, Franssen GM, Herrmann K, Boerman OC, et al
    In Vitro and In Vivo Characterization of an (18)F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts.
    J Nucl Med. 2019;60:1017-1022.
    PubMed     Abstract available


    June 2019
  47. RAY BANERJEE S, Minn IL, Kumar V, Josefsson A, et al
    Preclinical evaluation of (203/212)Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer.
    J Nucl Med. 2019 Jun 28. pii: jnumed.119.229393. doi: 10.2967/jnumed.119.229393.
    PubMed     Abstract available


  48. ROWE SP, Campbell SP, Mana-Ay M, Szabo Z, et al
    Prospective Evaluation of PSMA-Targeted (18)F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    J Nucl Med. 2019 Jun 14. pii: jnumed.119.226514. doi: 10.2967/jnumed.119.226514.
    PubMed     Abstract available


  49. GAMBHIR SS, Shankar LK, Rosenthal E, Warram JM, et al
    Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities-Phase III Studies.
    J Nucl Med. 2019;60:736-744.
    PubMed    


  50. EMMETT L, Metser U, Bauman G, Hicks RJ, et al
    Prospective, Multisite, International Comparison of (18)F-Fluoromethylcholine PET/CT, Multiparametric MRI, and (68)Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and P
    J Nucl Med. 2019;60:794-800.
    PubMed     Abstract available


  51. RATHKE H, Flechsig P, Mier W, Bronzel M, et al
    Dosimetry Estimate and Initial Clinical Experience with (90)Y-PSMA-617.
    J Nucl Med. 2019;60:806-811.
    PubMed     Abstract available


    May 2019
  52. ZACHO H, Jochumsen MR, Langkilde NC, Mortensen JC, et al
    No added value of (18)F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy.
    J Nucl Med. 2019 May 30. pii: jnumed.119.229062. doi: 10.2967/jnumed.119.229062.
    PubMed     Abstract available


  53. SATHEKGE M, Bruchertseifer F, Vorster M, Lawal I, et al
    PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING (225)Ac-PSMA-617 RADIOLIGAND THERAPY.
    J Nucl Med. 2019 May 17. pii: jnumed.119.229229. doi: 10.2967/jnumed.119.229229.
    PubMed     Abstract available


  54. CARRASQUILLO JA, Fine B, Pandit-Taskar N, Larson SM, et al
    Imaging metastatic castration-resistant prostate cancer patients with (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody.
    J Nucl Med. 2019 May 3. pii: jnumed.118.222844. doi: 10.2967/jnumed.118.222844.
    PubMed     Abstract available


  55. KELLY JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, et al
    Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    J Nucl Med. 2019;60:656-663.
    PubMed     Abstract available


  56. GAFITA A, Rauscher I, Retz M, Knorr K, et al
    Early Experience of Rechallenge (177)Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer.
    J Nucl Med. 2019;60:644-648.
    PubMed     Abstract available


  57. KELLY JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, et al
    A Single Dose of (225)Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model.
    J Nucl Med. 2019;60:649-655.
    PubMed     Abstract available


    April 2019
  58. PIRON S, De Man K, Van Laeken N, D'Asseler Y, et al
    Radiation dosimetry and biodistribution of (18)F-PSMA-11 for PET imaging of prostate cancer.
    J Nucl Med. 2019 Apr 26. pii: jnumed.118.225250. doi: 10.2967/jnumed.118.225250.
    PubMed     Abstract available


  59. JANSEN BHE, Yaqub M, Voortman J, Cysouw MCF, et al
    Simplified Methods for Quantification of (18)F-DCFPyL Uptake in Patients with Prostate Cancer.
    J Nucl Med. 2019 Apr 18. pii: jnumed.119.227520. doi: 10.2967/jnumed.119.227520.
    PubMed     Abstract available


  60. ROUSSEAU E, Wilson D, Lacroix-Poisson F, Krauze A, et al
    A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.
    J Nucl Med. 2019 Apr 12. pii: jnumed.119.226381. doi: 10.2967/jnumed.119.226381.
    PubMed     Abstract available


  61. LINDEMANN ME, Guberina N, Wetter A, Fendler W, et al
    Improving 68-Ga-PSMA PET/MR hybrid imaging of the prostate with un-renormalized absolute scatter correction.
    J Nucl Med. 2019 Apr 12. pii: jnumed.118.224139. doi: 10.2967/jnumed.118.224139.
    PubMed     Abstract available


  62. ABIODUN-OJO OA, Akintayo AA, Akin-Akintayo OO, Tade FI, et al
    (18)F-Fluciclovine parameters on targeted prostate biopsy associated with true positivity in recurrent prostate cancer.
    J Nucl Med. 2019 Apr 6. pii: jnumed.119.227033. doi: 10.2967/jnumed.119.227033.
    PubMed     Abstract available


    March 2019
  63. JADVAR H, Velez E, Desai B, Ji L, et al
    Prediction of time to hormonal treatment failure in metastatic castrate-sensitive prostate cancer with (18)F-FDG PET/CT.
    J Nucl Med. 2019 Mar 29. pii: jnumed.118.223263. doi: 10.2967/jnumed.118.223263.
    PubMed     Abstract available


  64. RAHBAR K, Hofman MS, Schrader AJ, Boegemann M, et al
    A Self-Fulfilling Prophecy: Comparing (177)Lu-PSMA Radioligand therapy in Taxane Naive vs Post-Taxane metastasized Prostate Cancer Patients?
    J Nucl Med. 2019 Mar 29. pii: jnumed.119.228742. doi: 10.2967/jnumed.119.228742.
    PubMed    


  65. SOEDA F, Watabe T, Naka S, Liu Y, et al
    Impact of (18)F-PSMA-1007 uptake in prostate cancer using different peptide concentrations: preclinical PET/CT study in mice.
    J Nucl Med. 2019 Mar 22. pii: jnumed.118.223479. doi: 10.2967/jnumed.118.223479.
    PubMed     Abstract available


  66. METSER U, Chua SS, Ho B, Punwani S, et al
    The contribution of multiparametric pelvic & whole body MR to interpretation of (18)F-fluoromethylcholine or (68)Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure following radical prostatectomy.
    J Nucl Med. 2019 Mar 22. pii: jnumed.118.225185. doi: 10.2967/jnumed.118.225185.
    PubMed     Abstract available


  67. EKMEKCIOGLU O, Busstra M, Klass ND, Verzijlbergen F, et al
    Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence - a narrative review of literature.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.222885. doi: 10.2967/jnumed.118.222885.
    PubMed     Abstract available


  68. ZHANG J, Kulkarni HR, Singh A, Schuchardt C, et al
    (177)Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.223149. doi: 10.2967/jnumed.118.223149.
    PubMed     Abstract available


  69. SCHWENCK J, Olthof SC, Pfannenberg C, Reischl G, et al
    Intention to treat analysis of (68)Ga-PSMA and (11)C-choline PET/CT versus CT for prostate cancer recurrences after surgery.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224543. doi: 10.2967/jnumed.118.224543.
    PubMed     Abstract available


  70. KRAMER GM, Yaqub M, Vargas HA, Schuit R, et al
    Assessment of simplified methods for quantification of (18)F-FDHT uptake in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.220111. doi: 10.2967/jnumed.118.220111.
    PubMed     Abstract available


  71. GAFITA A, Bieth M, Kroenke M, Tetteh G, et al
    qPSMA: a semi-automatic software for whole-body tumor burden assessment in prostate cancer using (68)Ga-PSMA11 PET/CT.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224055. doi: 10.2967/jnumed.118.224055.
    PubMed     Abstract available


    February 2019
  72. LIU T, Liu C, Xu X, Liu F, et al
    Preclinical evaluation and pilot clinical study of Al(18)F-PSMA-BCH for prostate cancer imaging.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.221671. doi: 10.2967/jnumed.118.221671.
    PubMed     Abstract available


    January 2019
  73. BARBER TW, Singh A, Kulkarni HR, Niepsch K, et al
    Clinical outcomes of (177)Lu-PSMA radioligand therapy in taxane chemotherapy pretreated and taxane chemotherapy naive patients with metastatic castration resistant prostate cancer.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.216820. doi: 10.2967/jnumed.118.216820.
    PubMed     Abstract available


  74. JILG CA, Drendel V, Rischke HC, Beck TIR, et al
    Detection Rate of (18)F-choline-PET/CT and (68)Ga-PSMA-HBED-CC-PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.220541. doi: 10.2967/jnumed.118.220541.
    PubMed     Abstract available


  75. BURGER IA, Muller J, Donati OF, Ferraro DA, et al
    (68)Ga-PSMA-11 PET/MR detects local recurrence occult on mpMRI in prostate cancer patients after HIFU.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.221564. doi: 10.2967/jnumed.118.221564.
    PubMed     Abstract available


  76. JOCHUMSEN MR, Tolbod LP, Pedersen BG, Nielsen MM, et al
    Quantitative tumor perfusion imaging with (82)Rubidium-PET/CT in prostate cancer - analytical and clinical validation.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.219188. doi: 10.2967/jnumed.118.219188.
    PubMed     Abstract available


  77. KLETTING P, Thieme A, Eberhardt N, Rinscheid A, et al
    Modeling and Predicting Tumor Response in Radioligand Therapy.
    J Nucl Med. 2019;60:65-70.
    PubMed     Abstract available


    December 2018
  78. MAURER T, van Leeuwen FWB, Schottelius M, Wester HJ, et al
    Entering the era of molecular-targeted precision surgery in recurrent prostate cancer.
    J Nucl Med. 2018 Dec 20. pii: jnumed.118.221861. doi: 10.2967/jnumed.118.221861.
    PubMed    


  79. SCHMIDT-HEGEMANN NS, Chukwuka E, Minglun L, Rogowski P, et al
    Impact of (68)Ga-PSMA-PET/CT on the radiotherapeutic approach for prostate cancer in comparison to CT - a retrospective analysis.
    J Nucl Med. 2018 Dec 14. pii: jnumed.118.220855. doi: 10.2967/jnumed.118.220855.
    PubMed     Abstract available


  80. CHEN M, Zhang Q, Zhang C, Zhao X, et al
    Combination of (68)Ga-PSMA PET/CT and multiparameter MRI improves the detection of clinically significant prostate cancer: a lesion by lesion analysis.
    J Nucl Med. 2018 Dec 14. pii: jnumed.118.221010. doi: 10.2967/jnumed.118.221010.
    PubMed     Abstract available


  81. EMMETT LM, Yin C, Crumbaker M, Hruby G, et al
    Rapid modulation of PSMA expression by Androgen deprivation: Serial (68)Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
    J Nucl Med. 2018 Dec 14. pii: jnumed.118.223099. doi: 10.2967/jnumed.118.223099.
    PubMed     Abstract available


  82. HOPE TA, Goodman JZ, Allen IE, Calais J, et al
    Meta-analysis of (68)Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.
    J Nucl Med. 2018 Dec 7. pii: jnumed.118.219501. doi: 10.2967/jnumed.118.219501.
    PubMed     Abstract available


    November 2018
  83. BEHR SC, Aggarwal R, Van Brocklin HF, Flavell RR, et al
    First-in-Human Phase I study of CTT1057, a Novel (18)F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer.
    J Nucl Med. 2018 Nov 21. pii: jnumed.118.220715. doi: 10.2967/jnumed.118.220715.
    PubMed     Abstract available


  84. ZLATOPOLSKIY BD, Endepols H, Krapf P, Guliyev M, et al
    Discovery of (18)F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions.
    J Nucl Med. 2018 Nov 2. pii: jnumed.118.218495. doi: 10.2967/jnumed.118.218495.
    PubMed     Abstract available


    October 2018
  85. VIOLET JA, Jackson P, Ferdinandus J, Sandhu S, et al
    Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and "whole body" tumor dosimetry with treatment outcomes.
    J Nucl Med. 2018 Oct 5. pii: jnumed.118.219352. doi: 10.2967/jnumed.118.219352.
    PubMed     Abstract available


    September 2018
  86. SCHOTTELIUS M, Wurzer A, Wissmiller K, Beck R, et al
    Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer.
    J Nucl Med. 2018 Sep 20. pii: jnumed.118.212720. doi: 10.2967/jnumed.118.212720.
    PubMed     Abstract available


  87. YIN Y, Werner RA, Higuchi T, Lapa C, et al
    Follow-Up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
    J Nucl Med. 2018 Sep 6. pii: jnumed.118.217653. doi: 10.2967/jnumed.118.217653.
    PubMed     Abstract available


  88. WERNER RA, Bundschuh RA, Bundschuh L, Javadi MS, et al
    Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on (18)F-DCFPyL PET/CT Imaging.
    J Nucl Med. 2018 Sep 6. pii: jnumed.118.217588. doi: 10.2967/jnumed.118.217588.
    PubMed     Abstract available


    August 2018
  89. TORRADO-CARVAJAL A, Vera-Olmos J, Izquierdo-Garcia D, Catalano OA, et al
    Dixon-VIBE Deep Learning (DIVIDE) Pseudo-CT Synthesis for Pelvis PET/MR Attenuation Correction.
    J Nucl Med. 2018 Aug 30. pii: jnumed.118.209288. doi: 10.2967/jnumed.118.209288.
    PubMed     Abstract available


  90. ROUSSEAU E, Lau J, Kuo HT, Zhang Z, et al
    Monosodium glutamate reduces (68)Ga-PSMA-11 uptake in salivary glands and kidneys in preclinical prostate cancer model.
    J Nucl Med. 2018 Aug 10. pii: jnumed.118.215350. doi: 10.2967/jnumed.118.215350.
    PubMed     Abstract available


    July 2018
  91. GIESEL FL, Knorr K, Spohn F, Will L, et al
    Detection efficacy of [(18)F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy.
    J Nucl Med. 2018 Jul 24. pii: jnumed.118.212233. doi: 10.2967/jnumed.118.212233.
    PubMed     Abstract available


  92. JADVAR H
    Oligometastatic prostate cancer: molecular imaging and clinical management implications in the era of precision oncology.
    J Nucl Med. 2018 Jul 20. pii: jnumed.118.213470. doi: 10.2967/jnumed.118.213470.
    PubMed    


  93. KOERBER SA, Will L, Kratochwil C, Haefner MF, et al
    (68)Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.
    J Nucl Med. 2018 Jul 5. pii: jnumed.118.211086. doi: 10.2967/jnumed.118.211086.
    PubMed     Abstract available


    May 2018
  94. LARIMER BM, Dubois F, Bloch E, Nesti S, et al
    Specific (18)F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models is Facilitated by Pre-Binding to Sex Hormone Binding Globulin.
    J Nucl Med. 2018 May 31. pii: jnumed.118.208785. doi: 10.2967/jnumed.118.208785.
    PubMed     Abstract available


  95. THALGOTT M, Duwel C, Rauscher I, Heck MM, et al
    One-stop shop whole-body (68)Ga-PSMA-11 PET/MRI compared to clinical Nomograms for preoperative T- and N-Staging of High-Risk Prostate Cancer.
    J Nucl Med. 2018 May 24. pii: jnumed.117.207696. doi: 10.2967/jnumed.117.207696.
    PubMed     Abstract available


  96. DOUGHTON JA, Hofman MS, Eu P, Hicks RJ, et al
    A first-in-man study of (68)Ga-nanocolloid PET-CT sentinel lymph node imaging in prostate cancer demonstrates aberrant lymphatic drainage pathways.
    J Nucl Med. 2018 May 4. pii: jnumed.118.209171. doi: 10.2967/jnumed.118.209171.
    PubMed     Abstract available


  97. ELSCHOT M, Selnaes KM, Johansen H, Kruger-Stokke B, et al
    The Effect of Including Bone in DIXON-based Attenuation Correction for (18)F-fluciclovine PET/MRI of Prostate Cancer.
    J Nucl Med. 2018 May 4. pii: jnumed.118.208868. doi: 10.2967/jnumed.118.208868.
    PubMed     Abstract available


    April 2018
  98. CALAIS J, Kishan AU, Cao M, Fendler WP, et al
    Potential impact of (68)Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.209387. doi: 10.2967/jnumed.118.209387.
    PubMed     Abstract available


  99. AHMADZADEHFAR H, Essler M
    Predictive factors of response and overall survival in patients with castration-resistant metastatic prostate cancer undergoing (177)Lu-PSMA therapy.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.209270. doi: 10.2967/jnumed.118.209270.
    PubMed    


  100. GRKOVSKI M, Gharzeddine K, Sawan P, Schoder H, et al
    (11)C-choline pharmacokinetics in recurrent prostate cancer.
    J Nucl Med. 2018 Apr 6. pii: jnumed.118.210088. doi: 10.2967/jnumed.118.210088.
    PubMed     Abstract available


  101. VARGAS HA, Kramer GM, Scott AM, Weickhardt A, et al
    Reproducibility and repeatability of semi-quantitative (18)F-fluorodihydrotestosterone (FDHT) uptake metrics in castration-resistant prostate cancer metastases: a prospective multi-center study.
    J Nucl Med. 2018 Apr 6. pii: jnumed.117.206490. doi: 10.2967/jnumed.117.206490.
    PubMed     Abstract available


    March 2018
  102. HARMON SA STEPHANIE., Bergvall E, Mena E, Shih JH, et al
    A Prospective Comparison of (18)F-Sodium Fluoride PET/CT and PSMA-targeted (18)F-DCFBC PET/CT in Metastatic Prostate Cancer.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.207373. doi: 10.2967/jnumed.117.207373.
    PubMed     Abstract available


  103. ZETTLITZ KA, Tsai WK, Knowles SM, Kobayashi N, et al
    Dual-modality immunoPET and near-infrared fluorescence (NIRF) imaging of pancreatic cancer using an anti-prostate cancer stem cell antigen (PSCA) cys-diabody.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.207332. doi: 10.2967/jnumed.117.207332.
    PubMed     Abstract available


  104. LUCKERATH K, Stuparu AD, Wei L, Kim W, et al
    Detection threshold and reproducibility of (68)Ga-PSMA11 PET/CT in a mouse model of prostate cancer.
    J Nucl Med. 2018 Mar 30. pii: jnumed.118.207704. doi: 10.2967/jnumed.118.207704.
    PubMed     Abstract available


  105. PARENT EE, Schuster DM
    Update on (18)F-fluciclovine PET for prostate cancer imaging.
    J Nucl Med. 2018 Mar 9. pii: jnumed.117.204032. doi: 10.2967/jnumed.117.204032.
    PubMed     Abstract available


  106. CALAIS J, Fendler WP, Herrmann K, Eiber M, et al
    Reply: Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way.
    J Nucl Med. 2018 Mar 1. pii: jnumed.118.209965. doi: 10.2967/jnumed.118.209965.
    PubMed    


  107. WONDERGEM M, van der Zant F, Vlottes P, Knol R, et al
    Effects of fasting on (18)F-DCFPyL uptake in prostate cancer lesions and tissues with known high physiologic uptake.
    J Nucl Med. 2018 Mar 1. pii: jnumed.117.207316. doi: 10.2967/jnumed.117.207316.
    PubMed     Abstract available


  108. HICKS RJ
    The Injustice of Being Judged by the Errors of Others: The Tragic Tale of the Battle for PET Reimbursement.
    J Nucl Med. 2018;59:418-420.
    PubMed    


  109. LUTJE S, Gerrits D, Molkenboer-Kuenen JD, Herrmann K, et al
    Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    J Nucl Med. 2018;59:494-501.
    PubMed     Abstract available


    February 2018
  110. DENES B, Gardiner P
    Comparison of (68)Ga-PSMA-11 PET/CT and (18)F-Fluciclovone PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Interesting, but Far from Definitive.
    J Nucl Med. 2018 Feb 23. pii: jnumed.118.209817. doi: 10.2967/jnumed.118.209817.
    PubMed    


  111. GIESEL F, Will L, Kesch C, Freitag M, et al
    Biochemical recurrence of prostate cancer: initial results with (18)F-PSMA-1007 PET/CT.
    J Nucl Med. 2018 Feb 1. pii: jnumed.117.196329. doi: 10.2967/jnumed.117.196329.
    PubMed     Abstract available


  112. WEBER W
    2017 SNMMI Highlights Lecture: Oncology, Part 2.
    J Nucl Med. 2018;59:9N-15N.
    PubMed    


    January 2018
  113. RATHKE H, Afshar-Oromieh A, Giesel FL, Kremer C, et al
    Intra-individual comparison of Tc-99m-MDP bone scan and the PSMA-ligand Tc-99m-MIP-1427 in patients with osseous metastasized prostate cancer.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.200220. doi: 10.2967/jnumed.117.200220.
    PubMed     Abstract available


  114. RISCHPLER C, Beck TI, Okamoto S, Schlitter AM, et al
    (68)Ga-PSMA-HBED-CC uptake in cervical, coeliac and sacral ganglia as an important pitfall in prostate cancer PET imaging.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.204677. doi: 10.2967/jnumed.117.204677.
    PubMed     Abstract available


  115. ROWE SP, Pomper MG, Gorin MA
    Molecular Imaging of Prostate Cancer: Choosing the Right Agent.
    J Nucl Med. 2018 Jan 25. pii: jnumed.117.206318. doi: 10.2967/jnumed.117.206318.
    PubMed    


  116. CALAIS J, Cao M, Nickols NG
    The Utility of PET/CT in External Radiation Therapy Planning of Prostate Cancer.
    J Nucl Med. 2018 Jan 4. pii: jnumed.117.196444. doi: 10.2967/jnumed.117.196444.
    PubMed     Abstract available


  117. WEBER W
    2017 SNMMI Highlights Lecture: Oncology.
    J Nucl Med. 2018;59:7N-13N.
    PubMed    


    December 2017
  118. GIESEL F, Will L, Lawal I, Lengana T, et al
    Intra-individual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study.
    J Nucl Med. 2017 Dec 21. pii: jnumed.117.204669. doi: 10.2967/jnumed.117.204669.
    PubMed     Abstract available


  119. CALAIS J, Fendler WP, Herrmann K, Eiber M, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and (18)F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203257. doi: 10.2967/jnumed.117.203257.
    PubMed     Abstract available


  120. CECI F, Fendler W, Eiber M
    A new type of prostate cancer imaging. Will (64)CuCl2 PET/CT flourish or vanish?
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.199885. doi: 10.2967/jnumed.117.199885.
    PubMed    


  121. JADVAR H, Ballas LK
    PSMA PET: Transformational Change in Prostate Cancer Management?
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203604. doi: 10.2967/jnumed.117.203604.
    PubMed    


  122. CALAIS J, Fendler WP, Eiber M, Gartmann J, et al
    Actual impact of (68)Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.202945. doi: 10.2967/jnumed.117.202945.
    PubMed     Abstract available


  123. HAMMES J, Tager P, Drzezga A
    EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203265. doi: 10.2967/jnumed.117.203265.
    PubMed     Abstract available


    November 2017
  124. BARANSKI AC, Schafer M, Bauder-Wust U, Roscher M, et al
    PSMA-11 Derived Dual-labeled PSMA-Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.
    J Nucl Med. 2017 Nov 30. pii: jnumed.117.201293. doi: 10.2967/jnumed.117.201293.
    PubMed     Abstract available


  125. ZHANG J, Niu G, Fan X, Lang L, et al
    Positron Emission Tomography Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198929. doi: 10.2967/jnumed.117.198929.
    PubMed     Abstract available


  126. CALAIS J, Czernin J, Cao M, Kishan AU, et al
    68Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.201749. doi: 10.2967/jnumed.117.201749.
    PubMed     Abstract available


  127. EIBER M, Herrmann K, Calais J, Hadaschihk B, et al
    PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198119. doi: 10.2967/jnumed.117.198119.
    PubMed     Abstract available


  128. GIESEL FL, Kopka K
    Reply: PSMA ligands for imaging prostate cancer - alternative labeling by complex formation with Al18F.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198176. doi: 10.2967/jnumed.117.198176.
    PubMed    


    October 2017
  129. MINAMIMOTO R, Sonni I, Hancock S, Vasanawala S, et al
    Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Conventional Imaging.
    J Nucl Med. 2017 Oct 30. pii: jnumed.117.197624. doi: 10.2967/jnumed.117.197624.
    PubMed     Abstract available


  130. HOFMAN MS, Eu P, Jackson P, Hong E, et al
    Cold Kit PSMA PET Imaging: Phase I study of 68Ga-THP-PSMA PET/CT in patients with prostate cancer.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.199554. doi: 10.2967/jnumed.117.199554.
    PubMed     Abstract available


  131. ELSCHOT M, Selnaes KM, Sandsmark E, Kruger-Stokke B, et al
    Combined 18F-Fluciclovine PET/MRI shows potential for detection and characterization of high-risk prostate cancer.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.198598. doi: 10.2967/jnumed.117.198598.
    PubMed     Abstract available


  132. DONIN NM, Reiter R
    Why targeting PSMA is a game changer in the management of prostate cancer - a Urologist's point of view.
    J Nucl Med. 2017 Oct 6. pii: jnumed.117.191874. doi: 10.2967/jnumed.117.191874.
    PubMed     Abstract available


  133. KRATOCHWIL C, Bruchertseifer F, Rathke H, Bronzel M, et al
    Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.
    J Nucl Med. 2017;58:1624-1631.
    PubMed     Abstract available


    September 2017
  134. IAGARU A
    Will GRPR Compete with PSMA as a Target in Prostate Cancer?
    J Nucl Med. 2017 Sep 28. pii: jnumed.117.198192. doi: 10.2967/jnumed.117.198192.
    PubMed    


  135. FENDLER WP, Cutler C
    More alpha than beta for prostate cancer?
    J Nucl Med. 2017 Sep 21. pii: jnumed.117.198333. doi: 10.2967/jnumed.117.198333.
    PubMed    


  136. PICCARDO A, Paparo F, Puntoni M, Righi S, et al
    64CuCl2 PET/CT in prostate cancer relapse.
    J Nucl Med. 2017 Sep 8. pii: jnumed.117.195628. doi: 10.2967/jnumed.117.195628.
    PubMed     Abstract available


  137. FOSBOL MO, Petersen PM, Kjaer A, Mortensen J, et al
    Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity.
    J Nucl Med. 2017 Sep 1. pii: jnumed.117.195677. doi: 10.2967/jnumed.117.195677.
    PubMed     Abstract available


  138. SANO K, Kanada Y, Kanazaki K, Ding N, et al
    Brachytherapy with Intratumoral Injections of Radiometal-Labeled Polymers That Thermoresponsively Self-Aggregate in Tumor Tissues.
    J Nucl Med. 2017;58:1380-1385.
    PubMed     Abstract available


    August 2017
  139. WOYTHAL N, Arsenic R, Kempkensteffen C, Miller K, et al
    Immunohistochemical validation of PSMA-expression measured by 68Ga-PSMA PET/CT in primary prostate cancer.
    J Nucl Med. 2017 Aug 3. pii: jnumed.117.195172. doi: 10.2967/jnumed.117.195172.
    PubMed     Abstract available


    July 2017
  140. AFAQ A, Alahmed S, Chen SH, Lengana T, et al
    68Ga-PSMA PET/CT impact on prostate cancer management.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.192625. doi: 10.2967/jnumed.117.192625.
    PubMed     Abstract available


  141. GRIVAS N, Wit E, Kuusk T, KleinJan G, et al
    The impact of adding sentinel node biopsy to extended pelvic lymph node dissection on the biochemical recurrence of prostate cancer patients treated with robot-assisted radical prostatectomy.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.195644. doi: 10.2967/jnumed.117.195644.
    PubMed     Abstract available


  142. EMMETT L EMMETTHRUB, Van Leeuwen P, Nandurkar R, Scheltema MJ, et al
    Treatment outcomes from 68GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET.
    J Nucl Med. 2017 Jul 26. pii: jnumed.117.196683. doi: 10.2967/jnumed.117.196683.
    PubMed     Abstract available


  143. SCHWARZENBOCK SM, Rauscher I, Bluemel C, Fendler WP, et al
    PSMA Ligands for PET-Imaging of Prostate Cancer.
    J Nucl Med. 2017 Jul 7. pii: jnumed.117.191031. doi: 10.2967/jnumed.117.191031.
    PubMed     Abstract available


    June 2017
  144. FENDLER WP, Rahbar K, Herrmann K, Kratochwil C, et al
    177Lu-PSMA radioligand therapy for prostate cancer.
    J Nucl Med. 2017 Jun 29. pii: jnumed.117.191023. doi: 10.2967/jnumed.117.191023.
    PubMed     Abstract available


  145. AL-MOMANI E, Machulla HJ
    PSMA ligands for imaging prostate cancer - alternative labeling by complex formation with Al18F.
    J Nucl Med. 2017 Jun 29. pii: jnumed.117.197996. doi: 10.2967/jnumed.117.197996.
    PubMed    


  146. ROACH PJ, Francis R, Emmett L, Hsiao E, et al
    The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study.
    J Nucl Med. 2017 Jun 23. pii: jnumed.117.197160. doi: 10.2967/jnumed.117.197160.
    PubMed     Abstract available


  147. HOFMAN MS
    Accuracy in the eye of the beholder: can we improve agreement in prostate cancer diagnostics with PSMA PET/CT?
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.192542. doi: 10.2967/jnumed.117.192542.
    PubMed    


  148. VINSENSIA M, Choyke PL, Hadaschik B, Holland-Letz T, et al
    68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.116.185033. doi: 10.2967/jnumed.116.185033.
    PubMed     Abstract available


  149. KOERBER SA, Utzinger MT, Kratochwil C, Kesch C, et al
    68Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters.
    J Nucl Med. 2017 Jun 15. pii: jnumed.117.190314. doi: 10.2967/jnumed.117.190314.
    PubMed     Abstract available


  150. OSMAN MM, Iravani A, Hofman MS, Hicks RJ, et al
    Detection of Synchronous Primary Malignancies with 68Ga-PSMA PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients.
    J Nucl Med. 2017 Jun 1. pii: jnumed.117.190215. doi: 10.2967/jnumed.117.190215.
    PubMed     Abstract available


    May 2017
  151. FENDLER WP, Stuparu AD, Evans-Axelsson S, Luckerath K, et al
    Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer.
    J Nucl Med. 2017 May 25. pii: jnumed.117.193359. doi: 10.2967/jnumed.117.193359.
    PubMed     Abstract available


  152. BIETH M, Kronke M, Tauber R, Dahlbender M, et al
    Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumour Burden in Prostate Cancer using 68Ga-PSMA-PET/CT.
    J Nucl Med. 2017 May 25. pii: jnumed.116.189050. doi: 10.2967/jnumed.116.189050.
    PubMed     Abstract available


  153. JACOBSON O, Chen H, Niu G, Kiesewetter DO, et al
    PET-guided evaluation and optimization of internalized antibody-drug conjugates targeting erythropoietin producing hepatoma A2 receptor.
    J Nucl Med. 2017 May 25. pii: jnumed.117.192245. doi: 10.2967/jnumed.117.192245.
    PubMed     Abstract available


  154. HOPE TA, Aggarwal R, Chee B, Tao D, et al
    Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.192476. doi: 10.2967/jnumed.117.192476.
    PubMed     Abstract available


  155. SCHMUCK S, von Klot CA, Henkenberens C, Sohns JM, et al
    Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
    J Nucl Med. 2017 May 18. pii: jnumed.117.193581. doi: 10.2967/jnumed.117.193581.
    PubMed     Abstract available


  156. HADASCHIK B, Boegemann M
    Why Targeting PSMA is a valuable addition in the management of castration-resistant prostate cancer: The Urologists' point of view.
    J Nucl Med. 2017 May 18. pii: jnumed.117.194753. doi: 10.2967/jnumed.117.194753.
    PubMed    


  157. KESCH C, Vinsensia M, Radtke JP, Schlemmer HP, et al
    Intra-individual comparison of 18F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study.
    J Nucl Med. 2017 May 4. pii: jnumed.116.189233. doi: 10.2967/jnumed.116.189233.
    PubMed     Abstract available


    April 2017
  158. WONDERGEM M, van der Zant F, Knol R, Lazarenko S, et al
    18F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes ; detection rate, image quality, activity kinetics and biodistribution.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.192658. doi: 10.2967/jnumed.117.192658.
    PubMed     Abstract available


  159. KELLY JM, Amor-Coarasa A, Nikolopoulou A, Wustemann T, et al
    Double Targeting Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
    J Nucl Med. 2017 Apr 27. pii: jnumed.116.188722. doi: 10.2967/jnumed.116.188722.
    PubMed     Abstract available


  160. YOUNG JD, Abbate V, Imberti C, Meszaros LK, et al
    68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room temperature, one-step kit-based radiolabeling.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.191882. doi: 10.2967/jnumed.117.191882.
    PubMed     Abstract available


  161. FENDLER WP, Calais J, Allen-Auerbach M, Bluemel C, et al
    68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study.
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190827. doi: 10.2967/jnumed.117.190827.
    PubMed     Abstract available


  162. KESCH C, Kratochwil C, Mier W, Kopka K, et al
    Gallium-68 or Fluorine-18 for prostate cancer imaging?
    J Nucl Med. 2017 Apr 13. pii: jnumed.117.190157. doi: 10.2967/jnumed.117.190157.
    PubMed     Abstract available


  163. MILLER MP, Kostakoglu L, Pryma D, Yu JQ, et al
    Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT.
    J Nucl Med. 2017 Apr 6. pii: jnumed.116.188375. doi: 10.2967/jnumed.116.188375.
    PubMed     Abstract available


    December 2016
  164. LI X, Rowe SP, Leal JP, Gorin MA, et al
    Quantitative Parameters in PSMA-targeted PET Imaging with 18F-DCFPyL: Variability in Normal Organ Uptake.
    J Nucl Med. 2016 Dec 8. pii: jnumed.116.179739.
    PubMed     Abstract available


    October 2016
  165. JADVAR H
    Radiotheranostics in Prostate Cancer: Introduction and Overview.
    J Nucl Med. 2016;57.
    PubMed    


    September 2016
  166. HOPE TA, Truillet CC, Ehman EC, Afshar-Oromieh A, et al
    Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.181800.
    PubMed     Abstract available


  167. JANI A, Schreibmann E, Rossi PJ, Shelton JW, et al
    Impact of Fluciclovine (18F) Positron Emission Tomography on Target Volume Definition for Post-Prostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial.
    J Nucl Med. 2016 Sep 8. pii: jnumed.116.176057.
    PubMed     Abstract available


    August 2016
  168. D'SOUZA JW, Hensley H, Doss M, Beigarten C, et al
    Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-based Positron Emission Tomography Radiotracers.
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.178780.
    PubMed     Abstract available


  169. ZHANG J, Niu G, Lang L, Li F, et al
    Clinical translation of a dual integrin alphavbeta3 and GRPR targeting PET radiotracer 68Ga-NOTA-BBN-RGD.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.177048.
    PubMed     Abstract available


    July 2016
  170. LIN C, Bradshaw TJ, Perk TG, Harmon S, et al
    Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
    J Nucl Med. 2016 Jul 21. pii: jnumed.116.177295.
    PubMed     Abstract available


    May 2016
  171. CYSOUW MC, Kramer GM, Hoekstra OS, Frings V, et al
    Accuracy and precision of partial volume correction in oncological PET/CT studies.
    J Nucl Med. 2016 May 26. pii: jnumed.116.173831.
    PubMed     Abstract available


    March 2016
  172. PIERT M, Montgomery J, Kunju LP, Siddiqui J, et al
    18F-choline PET/MRI: the Additional Value of PET for MRI-guided Transrectal Prostate Biopsies.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.170878.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: